Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- Kyowa Hakko Kirin Starts Domestic PIII Trial for KW-3357
July 11, 2011
- Approvals for 3 Dasen-Like Drugs to Be Withdrawn
July 11, 2011
- AnGes MG Obtains Substance Patent for Novel Peptide AG-30 in Japan
July 11, 2011
- METI's Council Proposes Review of Patients' Drug Copayments
July 11, 2011
- Sawai May Embark on Follow-on Antibody Drugs in Mid-2010s: President Sawai
July 11, 2011
- Application for Partial Changes Acceptable When Crystal Form Is Changed: Korosho
July 11, 2011
- Towa to Actively Develop Value Added Generics
July 11, 2011
- Korosho to Study Application of Cost-Benefit Assessment to Reimbursement Pricing
July 11, 2011
- Research-oriented Companies Provide Reliable Info. on Generics: Prof. Kobayashi
July 11, 2011
- PMDA to Bring Domestic GMP into Greater Harmony with PIC/S GMP
July 11, 2011
- Hospitals Lose Money by Using Herceptin for Stomach Cancer: Chuikyo's DPC Subcommittee
July 11, 2011
- Sanofi-aventis K.K. Aiming for Growth in “Upper Single Digits” Pres. Moulding
July 11, 2011
- Differences in Legal Positioning of Package Inserts between Japan, US, Europe Highlighted
July 11, 2011
- Rivastigmine “Highly Effective”in Early Treatment of AD: Prof. Nakamura
July 11, 2011
- Nihon Chouzai to Invest ¥10 Bil. to Increase GE Production Capacity
July 4, 2011
- Anticancer Drug Market in Japan to Exceed ¥1 Tril. in 2019: Fuji-Keizai
July 4, 2011
- Pfizer Japan to Promote Established Products with Force of 1,000
July 4, 2011
- Drug Market for Metabolic Diseases to Grow to ¥430 Bil. in 2019: Fuji-Keizai
July 4, 2011
- MTPC Expects 8 Launches in FY2011
July 4, 2011
- Generics of Actos Listed from 18 Companies
July 4, 2011
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…